Loading…
Memory modulation with peripherally acting cholinergic drugs
Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize th...
Saved in:
Published in: | Psychopharmacologia 1992-03, Vol.106 (3), p.375-382 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343 |
---|---|
cites | cdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343 |
container_end_page | 382 |
container_issue | 3 |
container_start_page | 375 |
container_title | Psychopharmacologia |
container_volume | 106 |
creator | RUSH, D. K STREIT, K |
description | Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia. |
doi_str_mv | 10.1007/BF02245421 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF02245421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1570386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</originalsourceid><addsrcrecordid>eNpFkE1LAzEYhIMotVYv3oU9eBJW3-TNxy54scWqUPGi5yWbTdrIfpHsIv33VlrsXOYwDwMzhFxTuKcA6mG-BMa44IyekCnlyFIGip2SKQBiilRk5-Qixm_YiWd8QiZUKMBMTsnju226sE2arhprPfiuTX78sEl6G3y_sUHX9TbRZvDtOjGbrvatDWtvkiqM63hJzpyuo706-Ix8LZ8_F6_p6uPlbfG0Sg1SOqTMKW1VxsrKSlcBijwvNZSomVDGKioclVI4xSUHkRtjHC8ZVzKX2pUZcpyRu32vCV2MwbqiD77RYVtQKP4eKI4P7OCbPdyPZWOrI7qfvMtvD7mORtcu6Nb4-I8JgQoFx1-WiGJE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Memory modulation with peripherally acting cholinergic drugs</title><source>Springer Online Journal Archives</source><creator>RUSH, D. K ; STREIT, K</creator><creatorcontrib>RUSH, D. K ; STREIT, K</creatorcontrib><description>Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/BF02245421</identifier><identifier>PMID: 1570386</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Amnesia - chemically induced ; Amnesia - psychology ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; Ganglionic Stimulants - antagonists & inhibitors ; Male ; Medical sciences ; Memory - drug effects ; Mice ; Neostigmine - pharmacology ; Neuropharmacology ; Parasympatholytics - pharmacology ; Parasympathomimetics - pharmacology ; Pharmacology. Drug treatments ; Physostigmine - pharmacology ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Scopolamine - antagonists & inhibitors ; Scopolamine - pharmacology</subject><ispartof>Psychopharmacologia, 1992-03, Vol.106 (3), p.375-382</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</citedby><cites>FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5537354$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1570386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUSH, D. K</creatorcontrib><creatorcontrib>STREIT, K</creatorcontrib><title>Memory modulation with peripherally acting cholinergic drugs</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.</description><subject>Amnesia - chemically induced</subject><subject>Amnesia - psychology</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Ganglionic Stimulants - antagonists & inhibitors</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Memory - drug effects</subject><subject>Mice</subject><subject>Neostigmine - pharmacology</subject><subject>Neuropharmacology</subject><subject>Parasympatholytics - pharmacology</subject><subject>Parasympathomimetics - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Physostigmine - pharmacology</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Scopolamine - antagonists & inhibitors</subject><subject>Scopolamine - pharmacology</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LAzEYhIMotVYv3oU9eBJW3-TNxy54scWqUPGi5yWbTdrIfpHsIv33VlrsXOYwDwMzhFxTuKcA6mG-BMa44IyekCnlyFIGip2SKQBiilRk5-Qixm_YiWd8QiZUKMBMTsnju226sE2arhprPfiuTX78sEl6G3y_sUHX9TbRZvDtOjGbrvatDWtvkiqM63hJzpyuo706-Ix8LZ8_F6_p6uPlbfG0Sg1SOqTMKW1VxsrKSlcBijwvNZSomVDGKioclVI4xSUHkRtjHC8ZVzKX2pUZcpyRu32vCV2MwbqiD77RYVtQKP4eKI4P7OCbPdyPZWOrI7qfvMtvD7mORtcu6Nb4-I8JgQoFx1-WiGJE</recordid><startdate>19920301</startdate><enddate>19920301</enddate><creator>RUSH, D. K</creator><creator>STREIT, K</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920301</creationdate><title>Memory modulation with peripherally acting cholinergic drugs</title><author>RUSH, D. K ; STREIT, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Amnesia - chemically induced</topic><topic>Amnesia - psychology</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Ganglionic Stimulants - antagonists & inhibitors</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Memory - drug effects</topic><topic>Mice</topic><topic>Neostigmine - pharmacology</topic><topic>Neuropharmacology</topic><topic>Parasympatholytics - pharmacology</topic><topic>Parasympathomimetics - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Physostigmine - pharmacology</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Scopolamine - antagonists & inhibitors</topic><topic>Scopolamine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUSH, D. K</creatorcontrib><creatorcontrib>STREIT, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUSH, D. K</au><au>STREIT, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Memory modulation with peripherally acting cholinergic drugs</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>1992-03-01</date><risdate>1992</risdate><volume>106</volume><issue>3</issue><spage>375</spage><epage>382</epage><pages>375-382</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>1570386</pmid><doi>10.1007/BF02245421</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3158 |
ispartof | Psychopharmacologia, 1992-03, Vol.106 (3), p.375-382 |
issn | 0033-3158 1432-2072 |
language | eng |
recordid | cdi_crossref_primary_10_1007_BF02245421 |
source | Springer Online Journal Archives |
subjects | Amnesia - chemically induced Amnesia - psychology Animals Behavior, Animal - drug effects Biological and medical sciences Ganglionic Stimulants - antagonists & inhibitors Male Medical sciences Memory - drug effects Mice Neostigmine - pharmacology Neuropharmacology Parasympatholytics - pharmacology Parasympathomimetics - pharmacology Pharmacology. Drug treatments Physostigmine - pharmacology Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Scopolamine - antagonists & inhibitors Scopolamine - pharmacology |
title | Memory modulation with peripherally acting cholinergic drugs |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T01%3A01%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Memory%20modulation%20with%20peripherally%20acting%20cholinergic%20drugs&rft.jtitle=Psychopharmacologia&rft.au=RUSH,%20D.%20K&rft.date=1992-03-01&rft.volume=106&rft.issue=3&rft.spage=375&rft.epage=382&rft.pages=375-382&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/BF02245421&rft_dat=%3Cpubmed_cross%3E1570386%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/1570386&rfr_iscdi=true |